Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mitoguazone · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Mitoguazone | DRUG | - |
Inclusion Criteria Patients must have: * HIV positivity by ELISA confirmed by Western blot. * AIDS-related NHL that is refractory or relapsed. * Life expectancy of at least 12 weeks. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: * C...
Mitoguazone is an investigational small molecule being studied for the treatment of Non-Hodgkin's Lymphoma, including in patients with AIDS-related disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Mitoguazone is being developed by Sanofi, a global pharmaceutical company listed on the stock exchange under the ticker symbol SNY. The drug is currently in Phase 2 clinical development for Non-Hodgkin's Lymphoma.
Mitoguazone is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. One Phase 2 trial has been completed, and no active trials are currently ongoing.
Mitoguazone has been studied in one completed Phase 2 clinical trial, identified as NCT00002348. This trial evaluated the drug in patients with AIDS-related Non-Hodgkin's Lymphoma in the United States, enrolling adults aged 18 years and older.
Yes, Mitoguazone is the same as mitoguazone dihydrochloride. The clinical trial NCT00002348, which studied the drug in AIDS-related Non-Hodgkin's Lymphoma, used the name mitoguazone dihydrochloride to refer to the same investigational agent.